The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of emicizumab (Hemlibra®, Genentech), a monoclonal antibody currently under review by the FDA for prevention of bleeding in patients who have hemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in hemophilia A, and inhibitors interfere with factor replacement therapy. Emicizumab was approved by the FDA in November of 2017.
Boston Marriott Cambridge
Cambridge, MA, 02142
The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.
Open to public comment until February 23, 2018 at 5pm ET. For more information on submitting a public comment, visit our engagement page.